Health & Biotech
Check Up: More clinical trials and FDA funding boost. Is this the end of biotech’s woes?
Health & Biotech
Who got what in the healthcare budget, and which ASX stocks could benefit
Health & Biotech
Dr Boreham’s Crucible: Can RATs in the ranks lead Atomo to our home-testing utopia?
Health & Biotech
Dimerix crucial Phase 3 trials advance, deliver multi-million R&D tax refund
Health & Biotech
ASX Health Stocks: CBD gel could become cornerstone therapy for hand arthritis, says Avecho
Health & Biotech
Big R&D refund for Opyl as its AI clinical trial recruitment platform takes off
Health & Biotech
ASX Health Stocks: OncoSil and PainChek set to embark on overseas expansion
Health & Biotech
Weed Week: Wastewater doesn’t lie, Aussie cannabis consumption increased in 2021
Health & Biotech
Incannex secures landmark deal, reinforcing position as a global medicinal cannabis and psychedelic powerhouse
Health & Biotech
ASX Health Stocks: 2 immunotherapy biotechs announce progress on clinical trials
Health & Biotech
Locked and loaded: InteliCare poised for growth with giant Optus, Bethanie deal
Health & Biotech
ASX Health Stocks: Neuren, Imugene and RadioPharm have sights on new clinical trials
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.